Loading...
XNAS
ICCC
Market cap51mUSD
Dec 05, Last price  
5.64USD
1D
8.25%
1Q
-10.90%
Jan 2017
-5.21%
Name

ImmuCell Corp

Chart & Performance

D1W1MN
XNAS:ICCC chart
P/E
P/S
1.93
EPS
Div Yield, %
Shrs. gr., 5y
3.67%
Rev. gr., 5y
14.06%
Revenues
26m
+51.64%
4,983,1424,801,2706,069,1874,633,6904,508,6464,386,1965,111,1435,389,9356,007,1767,596,87410,228,6899,543,96110,431,00010,986,00013,723,00015,342,00019,243,00018,568,00017,471,66926,493,169
Net income
-2m
L-62.65%
707,782647,137662,138-468,557-216,493-384,684-409,51089,512117,395-167,1591,213,239508,448-168,000-2,322,000-1,296,000-1,022,000-78,000-2,494,000-5,774,598-2,156,629
CFO
358k
P
764,7771,358,036349,55753,137-109,665-808,613-37,315344,3901,098,660302,3642,900,236-323,9021,175,823-373,404233,5111,315,578954,170-1,543,871-4,674,236357,903

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and markets products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. It offers First Defense, an orally delivered scours preventive product for newborn dairy and beef calves; and Tri-Shield First Defense, a passive antibody product for the treatment of E. coli, coronavirus, and rotavirus. The company also provides California Mastitis Test that is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic; and Dual-Force First Defense, including a whey protein concentrate for the nutritional and feed supplement markets. In addition, it is involved in developing Re-Tain, a Nisin-based intramammary treatment of subclinical mastitis in lactating dairy cows. It sells its products through animal health distributors. ImmuCell Corporation was incorporated in 1982 and is headquartered in Portland, Maine.
IPO date
May 01, 1987
Employees
66
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT